0000000000696818

AUTHOR

Ulrich Mack

showing 2 related works from this author

Humoral immune responses of lung cancer patients against tumor antigen NY-ESO-1

2005

The cancer-associated antigen NY-ESO-1 is expressed in a number of malignancies of different histological type. Patients with NY-ESO-1 expressing tumors have been shown to bear circulating autoantibodies against this antigen. In this study, we have assessed the NY-ESO-I autoantibody response in patients with lung cancer by a serum ELISA. Using a serum dilution of 1:400 we detected seroreactivity in 35 of 175 (20%) of patients. Incidence of autoantibodies was significantly higher in patients suffering from non small cell lung cancer (NSCLC, 23%) as compared to those with small cell lung cancer (SCLC, 9%). In the NSCLC group, NY-ESO-I antibody was significantly more frequent in patients with …

MaleCancer ResearchPathologymedicine.medical_specialtyLung NeoplasmsAntibodies NeoplasmEnzyme-Linked Immunosorbent AssayAdenocarcinomaAntigenAntigens NeoplasmCarcinoma Non-Small-Cell LungmedicineHumansCarcinoma Small CellLung cancerAgedAutoantibodiesbiologybusiness.industryAutoantibodyMembrane ProteinsCancerCell DifferentiationMiddle Agedmedicine.diseaseTumor antigenrespiratory tract diseasesOncologyCarcinoma Squamous Cellbiology.proteinAdenocarcinomaFemaleAntibodyNY-ESO-1businessCancer Letters
researchProduct

CrELISA: a fast and robust enzyme-linked immunosorbent assay bypassing the need for purification of recombinant protein

2004

A multitude of antigens has been recently identified by screening of cDNA expression libraries derived from human tumors with autologous sera. Using a phage autoantibody assay and small panels of sera derived from cancer patients or controls it has been shown that some of these antigens display cancer-associated autoantibody responses. The diagnostic and prognostic significance of these potentially cancer-related autoantibodies remains unclear until large-scale assays are developed and serological data are available for hundreds of cancer patients and controls. The major bottleneck for the development of large-scale assays are the cloning, expression and the purification of each of the resp…

Antibodies NeoplasmImmunologyEnzyme-Linked Immunosorbent AssayBiologyAutoantigensSerologylaw.inventionAntigenAntigens NeoplasmlawEscherichia colimedicineHumansImmunology and AllergyAutoantibodiesCloningchemistry.chemical_classificationAutoantibodyMembrane ProteinsCancermedicine.diseaseVirologyMolecular biologyRecombinant ProteinsTumor antigenEnzymechemistryRecombinant DNAJournal of Immunological Methods
researchProduct